Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects

Journal of the American College of Cardiology

Volumn 39, Issue 7, 2002, Pages 1083-1095

  Valli, Georgianne ^a   Giardina, Elsa Grace V ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AESCULUS HIPPOCASTANUM EXTRACT; BELLADONNA ALKALOID; CLONIDINE; CRATAEGUS EXTRACT; DIGITALIS; DONG QUAI EXTRACT; EPHEDRA SINICA EXTRACT; GARLIC EXTRACT; GINGER EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HELLEBORE EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; KAVA; LICORICE EXTRACT; METHYSERGIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIZOTIFEN; SALVIA MILTIORRHIZA EXTRACT; SEROTONIN ANTAGONIST; TANACETUM PARTHENIUM EXTRACT; TICLOPIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; WARFARIN; YOHIMBINE;

CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTICENTER STUDY; OLEANDER; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; VITAMIN SUPPLEMENTATION;

ADULT; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DRUG INTERACTIONS; HUMANS; PHYTOTHERAPY; PLANT PREPARATIONS;

EID: 0037012369     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)01749-7     Document Type: Review

References (200)

1. Complementary medicine and the general practitioner
2. The booming U.S. botanical market: A new overview
3. Trends in alternative medicine use in the United States, 1990-1997
4. Nonvitamin, nonmineral dietary supplements: Issues and findings from NHANES III
5. Herbal products begin to attract the attention of brandname companies
6. Growing use of medicinal botanicals forces assessment by drug regulators
7. Research into complementary and alternative medicine: Problems and potential
8. What do commercial ginseng preparations contain?
9. Evaluation of commercial ginseng products
10. Garlic powder for hyperlipidemia - Analysis of recent negative results
11. Parthenolide content and bioactivity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of commercial and authenticated feverfew products
12. Introduction
13. Health in China
14. Herbal medicinals
15. Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen Elderly Study
16. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women
17. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study
18. Flavonoid intake and coronary mortality in Finland: A cohort study
19. Flavonoids - Chemistry, metabolism, cardioprotective effects, and dietary sources
20. Phytochemicals and cardiovascular disease
21. Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction
22. The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers
23. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
24. Iron chelation by deferoxamine inhibits lipid peroxidation during cardiopulmonary bypass in humans
25. Vitamin E for coronary bypass surgery
26. Deferoxamine reduces neutrophil-mediated free radical production during cardiopulmonary bypass in man
27. Variability in commercial ginseng products: And analysis of 25 preparations
28. Herb-drug interactions
29. Adulterants in Asian patent medicines
30. Harmless herbs? A review of the recent literature
31. Cardiovascular pharmacology of Panax notoginseng (Burk) F.H. Chen and Salvia miltiorrhiza
32. Certain progress in the treatment of coronary heart disease with traditional medicinal plants in China
33. Protective action of seven natural phenolic compounds against peroxidative damage to biomembranes
34. Increase of vitamin E content in LDL and reduction of atherosclerosis in cholesterol-fed rabbits by a water-soluble antioxidant-rich fraction of Salvia miltiorrhiza
35. The effect of a medicinal Chinese herb on platelet function
36. New platelet aggregation inhibitors from tanshen
37. Effect of Xinmaitong capsule on damage of lipid peroxidation in coronary heart disease patients with myocardial ischemia
38. Therapeutic effect of sodium tanshinone IIA sulfonate in patients with coronary heart disease
39. Studies on cardiovascular actions of Salvia miltiorrhiza
40. Drug interactions as a cause of overanticoagulation and bleedings in Chinese patients receiving warfarin
41. Chinese herbs and warfarin potentiation by "danshen"
42. The effects of danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats
43. Progress in the medicinal chemistry of the herb feverfew
44. Feverfew as a preventive treatment for migraine: A systematic review
45. A chloroform extract of the herb feverfew blocks voltage-dependent potassium currents recorded from single smooth muscle cells
46. The flavonoids of Tanacetum parthenium T. vulgare and their anti-inflammatory properties
47. Extracts of feverfew inhibit granule secretions in blood platelets and polymorphonuclear leucocytes
48. Feverfew and vascular smooth muscle: Extracts from fresh and dried plants show opposing pharmacological profiles, dependent upon sesquiterpene lactone content
49. Efficacy of feverfew as prophylactic treatment of migraine
50. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention
51. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: A double-blind placebo-controlled study
52. Herbal medicines in migraine prevention
53. Is feverfew a pharmacologic agent?
54. Garlic shows promise for improving some cardiovascular risk factors
55. Garlic and onions: Their effect on eicosanoid metabolism and its clinical relevance
56. Inhibition of whole blood platelet-aggregation by compounds in garlic clove extracts and commercial garlic products
57. Therapeutic actions of garlic constituents
58. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: A case report
59. Warfarin and garlic
60. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: Nature of the evidence
61. Garlic powder in the treatment of moderate hyperlipidemia: A controlled trial and meta-analysis
62. Effect of garlic on total serum cholesterol. A meta-analysis
63. Garlic as a lipid lowering agent - A meta-analysis
64. Garlic for treating hypercholesterolemia
65. Comparison of the efficacy and tolerance of a garlic preparation vs. bezafibrate
66. Potent activation of nitric oxide synthase by garlic: A basis for its therapeutic applications
67. Can garlic lower blood pressure? A pilot study
68. Hypertension and hyperlipidemia: Garlic helps in mild cases
69. A meta-analysis of the effect of garlic on blood pressure
70. An evaluation of garlic and onion as antithrombotic agents
71. Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease
72. Mechanism by which garlic (Allium sativum) inhibits cyclooxygenase activity. Effect of raw versus boiled garlic extract on the synthesis of prostanoids
73. Effect of ajoene, the major anti-platelet compound from garlic, on platelet thrombus formation
74. Garlic as a possible risk for postoperative bleeding
75. Effects of garlic on thrombocyte aggregation, microcirculation and other risk factors
76. Effect of dried garlic on blood coagulation, fibrinolysis, platelet aggregation and serum cholesterol levels in patients with hyperlipoproteinemia
77. Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects
78. Effects of garlic coated tablets in peripheral arterial occlusive disease
79. Effects of garlic on platelet aggregation: A randomized placebo-controlled double-blind study
80. Effect of essential oil of garlic on serum fibrinolytic activity in patients with coronary artery disease
81. The effect of fried versus raw garlic on fibrinolytic activity in man
82. Effects of garlic on blood fluidity and fibrinolytic activity: A randomized, placebo-controlled, double-blind study
83. Lack of efficacy of dried garlic in patients with hyperlipoproteinemia
84. Effects of garlic on atherosclerosis
85. Prevention of hypercholesterolemic atherosclerosis by garlic, an antioxidant
86. Garlic for peripheral arterial occlusive disease
87. The antiatheroscleroric effect of Allium sativum
88. Ginkgo biloba
89. Approved herbs
90. Ginkgo biloba extract for the treatment of intermittent claudication: A meta-analysis of randomized trials
91. Spontaneous bilateral subdural hematomas associated with chronic ginkgo biloba ingestion
92. Subarachnoid haemorrhage associated with ginkgo biloba
93. Spontaneous hyphema associated with ingestion of ginkgo biloba extract
94. Association of Ginkgo biloba with intracerebral hemorrhage
95. Coma in a patient with Alzheimer's disease taking low dose trazodone and ginkgo biloba
96. Influence of extract of ginkgo biloba on cerebral blood flow and metabolism
97. A double-blind placebo-controlled trial of ginkgo biloba extract in acute cerebral ischaemia
98. Ginkgo biloba for cerebral insufficiency
99. Nachweis der therapeutischen wirksamkeit eines ginko biloba-spezialextraktes
100. Effectiveness of a ginkgo special extract on psychometric parameters in patients with vascular dementia
101. Ginkgo biloba extract: Mechanisms and clinical indications
102. Clinical and psychometric evaluation of Ginkgo biloba extract in chronic cerebrovascular diseases
103. Disorders of brain performance of vascular origin. Randomized double-blind study of the effectiveness of Ginkgo biloba extract
104. 2 on TNF, iNOS, and COX-2 expression in activated macrophages
105. Pharmacological management of intermittent claudication: A meta-analysis of randomised trials
106. Cardioprotective and anti-oxidant effects of the terpenoid constituents of ginkgo biloba extract (Egb 761)
107. Complementary cardioprotective effects of flavonoid metabolites and terpenoid constituents of Ginkgo biloba extract (EGb 761) during ischemia and reperfusion
108. Protection of mitochondrial respiration activity by bilobalide
109. Reactive oxygen species-induced apoptosis in PC12 cells and protective effect of bilobalide
110. Ginkgo biloba extract (EGB 761) pretreatment limits free radical-induced oxidative stress in patients undergoing coronary bypass surgery
111. Role of platelet-activating factor in cardiovascular pathology
112. Effect of a ginkgolide mixture (BN 52063) in antagonizing skin and platelet responses to platelet activating factor in man
113. Recent progress in ginkgolide research
114. Cedemin, a Ginkgo biloba extract, should not be considered as a PAF antagonist
115. Extracts of ginkgo biloba and bleeding or haemorrhage
116. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers
117. Ginseng pharmacology: Multiple constituents and multiple actions
118. Ginseng - Is there a use in clinical medicine?
119. Panax ginseng pharmacology: A nitric oxide link?
120. Effects of red ginseng on the congestive heart failure and its mechanism
121. Clinical and experimental study of improving left ventricular diastolic function by total saponins of panax notoginseng
122. Effect of Sheng Mai decoction on left ventricular function in patients with coronary heart disease
123. Effect of red ginseng on blood pressure in patients with essential hypertension and white coat hypertension
124. Ginseng abuse syndrome
125. Ginseng and high blood pressure
126. Traditional remedies and food supplements
127. Protective effects of ginsenoside on myocardial ischemic and reperfusion injuries
128. Probable interaction between warfarin and ginseng
129. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng
130. Siberian ginseng toxicity may be a case of mistaken identity
131. Ginseng-induced diuretic resistance
132. Protective effect of Crataegus extract on the cardiac mechanical dysfunction in isolated perfused working rat heart
133. Effect of a hawthorn extract on contraction and energy turnover of isolated rat cardiomyocytes
134. Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet
135. Hypolipidemic activity of tincture of Crataegus in rats
136. Crataegus special extract WS 1442: Assessment of objective effectiveness in patients with heart failure
137. Crataegus special extract WS 1442 in NYHA II heart failure. A placebo-controlled randomized double-blind study
138. Treatment of decreasing cardiac performance (NYHA Stages I to II) in advanced age with standardized Crataegus extract
139. High-dose Crataegus extract WS 1442 in the treatment of NYHA stage II heart failure
140. Survival and prognosis: Investigation of Crataegus extract WS 1442 in congestive heart failure (SPICE) - Rationale, study design and study protocol
141. Toxicity of Crataegus (hawthorn) extract (WS 1442)
142. Specific toxicologic considerations of selected herbal products
143. A possible role of lysosomal enzymes in the pathogenesis of varicosis and the reduction in their serum activity by Venostasin®
144. 2-alpha
145. Horse-chestnut seed extract for chronic venous insufficiency. A criteria-based systematic review
146. Hydroxyethylrutosides. A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders
147. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency
148. A case of Venoplant®-induced hepatic injury
149. Pseudo-(Venocuran-)Lupus - Eine kleine episode medizingeschichte
150. Pharmacokinetics and cardiovascular effects of ma-huang (Ephedra sinica) in normotensive adults
151. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids
152. Liquid chromatographic determination of methylxanthines and catechins in herbal preparations containing guarana
153. Hypersensitivity myocarditis associated with ephedra use
154. Potentiation of warfarin by dong quai
155. Danggui (Angelica sinensis) affects the pharmacodynamics but not the pharmacokinetics of warfarin in rabbits
156. Dong quai
157. Effects of radix Angelicae sinensis on hemorheology in patients with acute ischemic stroke
158. Does dong quai have estrogenic effects in postmenopausal women?
159. Ginger
160. Effect of dried ginger on human platelet function
161. Consumption of ginger (Zingiber officinale roscoe) does not affect ex vivo platelet thromboxane production in humans
162. Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigonella foenumgraecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease
163. Pharmacological studies on ginger. II. Pressor action of (6)-shogaol in anesthetized rats, or hindquarters, tail and mesenteric vascular beds of rats
164. ++-pumping adenosine triphosphate of sarcoplasmic reticulum, in guinea pig atrial muscle
165. Chapter 33: Antihypertensive agents and the drug therapy of hypertension
166. Intoxication from Veratrum album
167. Poisoning due to ingestion of Veratrum viride (false hellebore)
168. The making of an herbal superstar
169. Kava-kava extract WS 1490 versus placebo in anxiety disorders - A randomized placebo-controlled 25-week outpatient trial
170. +-channels in rat CA1 hippocampal neurons
171. Antithrombotic action of the kava pyrone (+)-kavain prepared from Piper methysticum on human platelets
172. Effects of the heavy usage of kava on physical health: Summary of a pilot survey in an Aboriginal community
173. Hepatitis associated with kava, a herbal remedy for anxiety
174. Coma from the health food store: Interaction between kava and alprazolam
175. Liquorice and its health implications
176. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess
177. Echocardiographic findings of the heart resembling dilated cardiomyopathy during hypokalemic myopathy due to licorice-induced pseudoaldosteronism
178. Herbal medications, nutraceuticals, and hypertension
179. Liquorice-induced hypertension - A new understanding of an old disease: Case report and brief review
180. Lesson of the week: Hypokalemia and hypertension associated with the use of liquorice flavoured chewing gum
181. Is blood pressure commonly raised by moderate consumption of liquorice?
182. Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists
183. Yohimbine effects on blood pressure and plasma catecholamines in human hypertension
184. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients
185. Oral yohimbine in human autonomic failure
186. Potential risks of health food products containing yohimbe extracts
187. Three cases of manic symptoms following yohimbine administration
188. Yohimbine-induced bronchospasm
189. Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome
190. Agranulocytosis associated with yohimbine use
191. Beneficial effect of digoxin-specific Fab antibody fragments in oleander intoxication
192. Acute yellow oleander (Thevetia peruviana) poisoning: Cardiac arrhythmias, electrolyte disturbances, and serum cardiac glycoside concentrations on presentation to hospital
193. Oleander toxicity: An examination of human and animal toxic exposures
194. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum)